Liraglutide and simethicone have some differences in long-term hypoglycemic effect, action, and adverse reactions, but no matter what kind of hypoglycemic drugs, they need to be used under the guidance of a doctor. For example, simepaglutide has a more stable hypoglycemic effect than liraglutide and can reduce body weight which is beneficial to cardiovascular and cerebral vessels, but the incidence of gastrointestinal discomforts and other adverse reactions is higher than that of liraglutide. Liraglutide and simethicone are both glucagon-like peptide-1 receptor agonists, and although they are both used in the treatment of type 2 diabetes in adults, they have different long-term effects. In the long run, simethicone can effectively reduce the indicators of glycated hemoglobin, fasting blood glucose, and self-tested blood glucose, and the effect of lowering glucose is more stable and lasting. Although liraglutide and simethicone are both hypoglycemic drugs, simethicone has both weight loss and cardiovascular protective effects, which can significantly reduce the body weight of diabetic patients, and at the same time can be used normally in people with normal body weight, which significantly reduces the risk of cardiovascular adverse events, and also has mild lipid-lowering and antihypertensive effects. The use of hypoglycemic drugs is recommended to be under the supervision of a physician and to seek medical attention in case of discomfort.